Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1 These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported … [Read more…]
Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as … [Read more…]
More than 9,000 nurses and PSW jobs could be lost by 2027-28 if government does not increase funding TORONTO–(BUSINESS WIRE)–Health care workers represented by the Canadian Union of Public Employees will hold a rally outside local Premier Doug Ford’s office in Etobicoke in response to funding cuts by the provincial government. The government’s fall economic … [Read more…]
NASHVILLE, Tenn.–(BUSINESS WIRE)–Matter Health, a medical group delivering on-site care inside senior-restricted affordable housing communities, today announced the appointment of Sarah Chouinard, MD, as Chief Medical Officer. In this role, Dr. Chouinard will oversee all aspects of clinical delivery and model performance, including quality outcomes, clinical programs, risk management, and overall model performance across Matter … [Read more…]
Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities LOS ANGELES–(BUSINESS WIRE)–$NAGE #Biotech—Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, … [Read more…]
SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 … [Read more…]
HOUSTON–(BUSINESS WIRE)–U.S. Physical Therapy, Inc. (“USPH” or the “Company”) (NYSE, NYSE Texas: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the fourth quarter and full year ended December 31, 2025. FINANCIAL HIGHLIGHTS Year Ended December 31, 2025 versus Year Ended December 31, 2024 … [Read more…]
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This … [Read more…]
This evolution formalizes shared decision-making and collaboration to support patients accessing faster, more coordinated care, close to home MULLICA HILL, N.J.–(BUSINESS WIRE)–Inspira Health announced an enhanced shared decision-making structure designed to further strengthen “systemness” across the organization. Through smaller, cross-functional teams, the new leadership structure will provide additional opportunities for leaders to share learnings, align … [Read more…]
New patient-specific solution expands Catalyst’s portfolio, enabling precise translation of 3D surgical plans into the operating room to reduce steps and increase accuracy NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Archer® Patient-Specific … [Read more…]
